CGIX - Cancer Genetics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.538
+0.002 (+0.35%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.536
Open0.550
Bid0.420 x 1000
Ask0.590 x 1800
Day's Range0.520 - 0.568
52 Week Range0.500 - 2.750
Volume108,357
Avg. Volume167,403
Market Cap14.928M
Beta (3Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-0.678
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing Cancer Genetics to pursue other opportunities. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability.

  • Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know
    Zacks14 days ago

    Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

    Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire28 days ago

    Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in China

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin® (TOO) Test in China. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Genecast Biotechnology has an impressive, well-established menu of tumor DNA testing and gene-based tests, and is the optimal partner to bring our TOO test to the China market. More specifically, CGI’s TOO test has the potential to improve lives of many cancer patients.

  • GlobeNewswirelast month

    Cancer Genetics Issues Letter to Shareholders

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders from its Chief Executive Officer Jay Roberts. Since I took on the role as Chief Executive Officer of the Company back in February 2018, we have made several positive advances in execution of our planned strategic direction in terms of our business and operations.

  • GlobeNewswirelast month

    Cancer Genetics and Cellaria Partner on Precision Medicine Tools

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models, today announced a new collaboration to develop extensive precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics will deploy its Genomics Center of Excellence to characterize Cellaria’s pipeline of commercial and custom-developed biopharma products. Cancer Genetics will leverage its biomarker and genomics testing capabilities to better understand patient diversity across clinical disease categories.

  • Business Wire2 months ago

    Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (CGIX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.

  • GlobeNewswire2 months ago

    Cancer Genetics Enters Supply Agreement with Agilent Technologies

    RUTHERFORD, N.J., Sept. 25, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and.

  • GlobeNewswire2 months ago

    Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

    RUTHERFORD, N.J., Sept. 20, 2018-- Cancer Genetics, Inc., a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful ...

  • PR Newswire2 months ago

    Chardan Advises NovellusDX in Cross-Border Biotech Merger

    NEW YORK , Sept. 18, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for ...

  • GlobeNewswire2 months ago

    Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis (with certain adjustments). Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market. This transaction will combine Cancer Genetics’ scale, expansive test portfolio and broad data set related to tumor biology, cultivated over more than a decade, with NovellusDx’s proprietary technology and machine learning capabilities to form a leading, oncology-focused precision medicine company.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CGIX earnings conference call or presentation 14-Aug-18 12:30pm GMT

    Q2 2018 Cancer Genetics Inc Earnings Call

  • Associated Press3 months ago

    Cancer Genetics: 2Q Earnings Snapshot

    The Rutherford, New Jersey-based company said it had a loss of 13 cents per share. The diagnostics company posted revenue of $7 million in the period. The company's shares closed at 98 cents. A year ago, ...

  • ACCESSWIRE3 months ago

    Cancer Genetics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: CGIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern ...

  • Benzinga3 months ago

    Cancer Genetics Q2 Earnings Preview

    On Tuesday, Cancer Genetics (NASDAQ: CGIX ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street analysts ...

  • ACCESSWIRE4 months ago

    Free Research Reports on DexCom and Three More Medical Research Stocks

    Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CGIX earnings conference call or presentation 15-May-18 12:30pm GMT

    Q1 2018 Cancer Genetics Inc Earnings Call

  • Business Wire5 months ago

    Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Cancer Genetics, Inc. (CGIX)

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the June 4, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ: CGIX) securities between March 23, 2017, and April 2, 2018, inclusive (the “Class Period”). To obtain information or actively participate in the class action, please visit the Cancer Genetics page on our website at www.glancylaw.com/case/cancer-genetics-inc. Investors suffering losses on their Cancer Genetics investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

  • ACCESSWIRE5 months ago

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 4, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cancer Genetics, Inc. ("Cancer Genetics" or ''the Company'') (NASDAQ: CGIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 23, 2017 and April 2, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before June 4, 2018.

  • ACCESSWIRE5 months ago

    FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) and Lead Plaintiff Deadline - June 4, 2018

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc. (''Cancer Genetics'' or the ''Company'') ...

  • ACCESSWIRE5 months ago

    3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cancer Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / June 1, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cancer Genetics, Inc. ("Cancer Genetics" or ''the Company'') (NASDAQ: CGIX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 23, 2017 and April 2, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before June 4, 2018.